Related Experiment Videos
[Expression and prognostic value of AKT2 in non-small cell lung cancer]
Xiaohui Miao1, Yong Song, Tangfeng Lv
1Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Background And Objective:
AKT2 is a critical actor in the PI3K signal transduction pathway. Activation of AKT2 can lead to cell growth and survival. It has been revealed that AKT2 play a central role in tumorigenesis, tumor growth as well as metastasis. The aim of this study is to investigate the association between AKT2 and the clinical outcome of non-small cell lung cancer (NSCLC) patients by detecting its expression levels in the tumor tissue samples.
Methods:
We developed an immunohistochemistry (IHC) assay to measure AKT2 protein levels in lung specimens from 80 cases with NSCLC and 10 cases with benign pulmonary disease.
Results:
The positive rate of AKT2 was 57.50% (46/80) in NSCLC, which was higher than that in benign pulmonary (10.0%) samples (Chi-square=8.038, P=0.006). There was no significant correlation between AKT2 expression and the clinicopathologic profiles. The expression of AKT2 was significantly correlated with the progression free survival (PFS) (Chi-square=12.671, P=0.005) and the overall survival (OS) (Chi-square=9.851, P=0.021) of patients with NSCLC.
Conclusion:
AKT2 may provide a prognostic bio-marker of NSCLC.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...